Introduction {#s1}
============

According to a statement of the Japanese Society for Dialysis Therapy, the total number of patients undergoing prolonged hemodialysis therapy in Japan was 334,505 as of the end of 2017, representing an increase of 4,896 patients compared with the previous year \[[@R01]\]. The most common primary disease affecting the increasing number of hemodialysis patients was diabetic nephropathy, which accounted for 45.6% of male patients and 35.8% of female patients. The mean age of all hemodialysis patients was 68.9 years for male patients and 71.4 years for female patients. A stratified analysis by 5-year age span showed the most common age group to be 75 - 79 years for male patients and 80 - 84 years for female patients. While attention should be paid to the effects of drug treatments and drug-induced renal disorders \[[@R02]\], the aforementioned background places importance to diabetic treatments in elderly Japanese patients, with renal effects in mind.

Dipeptidyl peptidase-4 (DPP-4) inhibitors selectively inhibit DPP-4, an enzyme that inactivates incretin in living organisms, to raise blood incretin concentrations and to stimulate glucose-dependent insulin secretion \[[@R03]\]. Many DPP-4 inhibitors have persistent effects when administered once daily, and hypoglycemia and body weight (BW) changes are unlikely \[[@R04]\]; they have been used commonly in Japan since their approval.

We previously reported the efficacy and safety of the DPP-4 inhibitor alogliptin used in 1-year treatment \[[@R05]\]. Many studies have so far reported on alogliptin, including the EXAMINE study, which reported that alogliptin treatment did not increase the mortality rate due to cardiovascular events or the hospitalization rate due to heart failure \[[@R06]\], and another study reporting that alogliptin significantly reduced the cardiovascular deaths and all-cause mortality rates in some populations \[[@R07]\]. In addition to clinical trial data, many studies in Japanese subjects reported the efficacy and safety of alogliptin \[[@R08]-[@R10]\], including a study reporting that alogliptin treatment lessened the progression of carotid atherosclerosis in terms of intima media thickness (IMT) in type 2 diabetic patients with no cardiovascular disease compared with conventional treatments \[[@R11]\] and good blood glucose control achieved even in long-term observation periods exceeding 3 years \[[@R12]\].

To assess the effects of alogliptin in elderly patients, Pratley et al conducted a meta-analysis of the results from six studies, reporting that alogliptin improved hemoglobin A1c (HbA1c) to extents similar to those in young patients, with no increased risks of hypoglycemia, BW gains, or other parameters compared with the young patients \[[@R13]\]. In addition, Rosenstock et al compared the 1-year effects of alogliptin and glipizide in elderly patients, reporting that alogliptin maintained blood glucose control equivalent to that with glipizide, with a much lower risk of hypoglycemia and no BW gain \[[@R14]\]. No study has focused on elderly Japanese patients, however; the meta-analysis by Pratley et al did not include Japanese clinical study results, and the study by Rosenstock et al reported US data only.

With this background, we analyzed compiled data for patients receiving alogliptin in an exploratory manner and assessed its efficacy and safety in elderly patients with type 2 diabetes (≥ 65 years).

Patients and Methods {#s2}
====================

Study design {#s2a}
------------

A multicenter retrospective observational study was conducted at clinics and hospitals belonging to the Kanagawa Physicians Association. Data were collected from the medical records of the subjects and the follow-up period was 1 year. This study was approved by the Ethics Review Board of the Kanagawa Physicians Association (May 23, 2013) (approval number: 2521).

Patients {#s2b}
--------

Patients were eligible for this study if they had type 2 diabetes mellitus (T2DM), were aged 20 years old or older, regularly attended a clinic or hospital belonging to the Kanagawa Physicians Association, and received treatment with alogliptin for 1 year or longer. Alogliptin was started if glycemic control was inadequate for at least 1 month despite diet and exercise therapy or diet and exercise plus oral antidiabetic drugs.

The exclusion criteria were as follows: a history of hypersensitivity to any component of alogliptin; a history of severe ketoacidosis, diabetic coma or precoma within 6 months before the start of alogliptin therapy; severe infection; recent or planned surgery or severe trauma; concurrent use of insulin preparations or glinides; and patients who the attending doctor considered to be inappropriate for this study for other reasons.

Items investigated {#s2c}
------------------

The baseline characteristics investigated for the subjects included the gender, age, height, duration of diabetes, family history, smoking history, alcohol history, and complications. Use of the following drugs was assessed before treatment with alogliptin, at the start of treatment, and 12 months after the start of treatment: alogliptin and other antidiabetic drugs. Efficacy endpoints were determined at each of the specified times, including HbA1c (National Glycohemoglobin Standardization Program value), blood glucose (fasting and postprandial), BW, body mass index (BMI), blood pressure (BP; systolic/diastolic), liver function parameters (glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, and γ-glutamyl transpeptidase), kidney function parameters (serum creatinine, estimated glomerular filtration rate (eGFR)), serum lipids (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs)), and serum amylase. In addition, adverse events were evaluated at each of these times to assess safety.

Statistical analysis {#s2d}
--------------------

After patients who did not receive the study drug were excluded from those whose case records were collected, the remaining patients formed the safety analysis set. The full analysis set (FAS) was obtained by excluding patients who met any of the following criteria from the safety analysis set: 1) No HbA1c data at the start of alogliptin treatment; 2) No HbA1c data after the start of alogliptin treatment; 3) Administration of another DPP-4 inhibitor after the start of alogliptin treatment; and 4) Patients for whom age data were not available.

Data were statistically analyzed in three age groups: \< 65 years, 65 - 74 years, and ≥ 75 years.

Patient characteristics were compared using analysis of variance (ANOVA) for continuous variables and Chi-square test for nominal variables. With regard to the efficacy in each of the three groups, a paired *t*-test was used to evaluate the changes in various parameters from baseline at months 3, 6, 9, and 12, and ANOVA was used for intergroup comparisons. With regard to eGFR, changes from month 3 values at months 6, 9, and 12 after treatment initiation were also evaluated by paired *t*-test. In all analyses, two populations were available: all subjects and subjects newly receiving alogliptin. Intragroup comparisons did not take multiplicity into account, and the significance level was set at 5% (two-sided). The analytical software R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria (<https://www.R-project.org/>)) was used for calculations. Data are presented as mean ± standard deviation or number (proportion) of patients.

Results {#s3}
=======

Of the 330 patients enrolled in the study 290 who met the selection criteria and did not meet any of the exclusion criteria were selected for the subanalysis set ([Fig. 1](#F1){ref-type="fig"}). Study population breakdown by age group was as follows: 110 patients (37.9%) at \< 65 years, 87 patients (30.0%) at 65 - 74 years, and 93 patients at ≥ 75 years (32.1%). The proportion of women and disease duration increased with increasing age, and the proportion of patients with hepatic steatosis, drinking history, or family history increased with younger age ([Table 1](#T1){ref-type="table"}). Similar tendencies were noted in the patients newly receiving alogliptin; however, there was no significant difference in sex ratio or incidence of hepatic steatosis in those patients (Supplementary [Table 1](#T1){ref-type="table"}, [www.jocmr.org](http://www.jocmr.org)).

![Participant flow.](jocmr-11-651-g001){#F1}

###### Baseline Characteristics

                                               Age \< 65             Age 65 - 74             Age ≥ 75                P              Unknown                   
  -------------------------------------------- --------------------- ----------------------- ----------------------- -------------- ------------ ------------ ------------
  Male/female                                  75 (68.2%)/33 (30%)   46 (52.9%)/41 (47.1%)   42 (45.2%)/49 (52.7%)   0.009\*        2 (1.8%)     0 (0%)       2 (2.2%)
  Age                                          54.8 ± 7.9            69.7 ± 2.9              79.8 ± 3.8              \< 0.001\*\*   0 (0%)       0 (0%)       0 (0%)
  Disease duration                             7.5 ± 5.5             11.5 ± 7.9              13 ± 8.4                \< 0.001\*\*   44 (40%)     32 (36.8%)   40 (43%)
  Diabetic retinopathy                         6 (5.5%)              11 (12.6%)              6 (6.5%)                0.249          18 (16.4%)   14 (16.1%)   21 (22.6%)
  Diabetic neuropathy                          4 (3.6%)              9 (10.3%)               13 (14%)                0.089          18 (16.4%)   18 (20.7%)   17 (18.3%)
  Diabetic nephropathy                         12 (10.9%)            10 (11.5%)              12 (12.9%)              0.837          15 (13.6%)   16 (18.4%)   17 (18.3%)
  Cerebrovascular disorders                    5 (4.5%)              8 (9.2%)                8 (8.6%)                0.502          19 (17.3%)   15 (17.2%)   21 (22.6%)
  Myocardial infarction                        2 (1.8%)              7 (8%)                  6 (6.5%)                0.223          19 (17.3%)   15 (17.2%)   21 (22.6%)
  Angina pectoris                              4 (3.6%)              13 (14.9%)              13 (14%)                0.029\*        19 (17.3%)   14 (16.1%)   21 (22.6%)
  Arteriosclerosis obliterans                  2 (1.8%)              4 (4.6%)                4 (4.3%)                0.477          22 (20%)     20 (23%)     26 (28%)
  Hypertension                                 54 (49.1%)            54 (62.1%)              60 (64.5%)              0.082          14 (12.7%)   12 (13.8%)   13 (14%)
  Dyslipidemia                                 64 (58.2%)            54 (62.1%)              44 (47.3%)              0.327          14 (12.7%)   12 (13.8%)   16 (17.2%)
  Hepatic steatosis                            26 (23.6%)            16 (18.4%)              6 (6.5%)                0.016\*        22 (20%)     23 (26.4%)   29 (31.2%)
  Others                                       20 (18.2%)            27 (31%)                28 (30.1%)              0.192          30 (27.3%)   18 (20.7%)   24 (25.8%)
  Smoking history                              24 (21.8%)            22 (25.3%)              12 (12.9%)              0.283          42 (38.2%)   32 (36.8%)   43 (46.2%)
  Drinking history                             43 (39.1%)            29 (33.3%)              14 (15.1%)              0.005\*        35 (31.8%)   30 (34.5%)   43 (46.2%)
  Family history                               29 (26.4%)            11 (12.6%)              9 (9.7%)                \< 0.001\*     51 (46.4%)   37 (42.5%)   61 (65.6%)
  Compliance with exercise; good or fair       47 (42.7%)            48 (55.2%)              36 (38.7%)              0.232          51 (46.4%)   30 (34.5%)   46 (49.5%)
  Compliance with diet therapy; good or fair   49 (44.5%)            47 (54%)                40 (43%)                0.325          49 (44.5%)   30 (34.5%)   46 (49.5%)

\*P \< 0.05, Chi-square test (excluding "Unknown" cases); \*\*P \< 0.05, ANOVA. ANOVA: analysis of variance.

There was no significant difference in the proportion of patients who were switched from other DPP-4 inhibitors among the three groups (27 patients, 24.5%, at \< 65 years; 28 patients, 32.2%, at 65 - 74 years; and 21 patients, 22.6%, at ≥ 75 years); however, concomitant use of biguanide (BG) decreased with increasing age ([Table 2](#T2){ref-type="table"}). The same tendency was found in the patients newly receiving alogliptin (Supplementary [Table 2](#T2){ref-type="table"}, [www.jocmr.org](http://www.jocmr.org)).

###### Medications of the Full Analysis Set

                                  Time         Age \< 65    Age 65 - 74   Age ≥ 75     P\*
  ------------------------------- ------------ ------------ ------------- ------------ ---------
  Number of applicable patients   0 M          110          87            93           
  12 M                            100          79           84                         
  DPP-4 inhibitors                Before       27 (24.5%)   28 (32.2%)    21 (22.6%)   0.302
  0 M                             110 (100%)   87 (100%)    93 (100%)     N/A          
  12 M                            100 (100%)   79 (100%)    84 (100%)     N/A          
  Sulfonylurea                    Before       38 (34.5%)   38 (43.7%)    41 (44.1%)   0.289
  0 M                             36 (32.7%)   38 (43.7%)   35 (37.6%)    0.289        
  12 M                            40 (40%)     34 (43%)     32 (38.1%)    0.811        
  Biguanide                       Before       36 (32.7%)   20 (23%)      14 (15.1%)   0.013\*
  0 M                             39 (35.5%)   24 (27.6%)   14 (15.1%)    0.004\*      
  12 M                            50 (50%)     24 (30.4%)   17 (20.2%)    \< 0.001\*   
  Thiazolidine                    Before       28 (25.5%)   12 (13.8%)    18 (19.4%)   0.125
  0 M                             22 (20%)     14 (16.1%)   16 (17.2%)    0.758        
  12M                             22 (22%)     9 (11.4%)    15 (17.9%)    0.178        
  α-glucosidase inhibitors        Before       25 (22.7%)   20 (23%)      26 (28%)     0.639
  0 M                             19 (17.3%)   11 (12.6%)   15 (16.1%)    0.659        
  12 M                            13 (13%)     10 (12.7%)   12 (14.3%)    0.948        
  Glinide                         Before       5 (4.5%)     4 (4.6%)      7 (7.5%)     0.588
  0 M                             0 (0%)       0 (0%)       0 (0%)        N/A          
  12 M                            0 (0%)       0 (0%)       0 (0%)        N/A          
  Insulin                         Before       0 (0%)       1 (1.1%)      0 (0%)       0.310
  0 M                             0 (0%)       0 (0%)       0 (0%)        N/A          
  12 M                            0 (0%)       0 (0%)       1 (1.2%)      0.343        

DPP-4: dipeptidyl peptidase-4; M: month; N/A: not applicable. \*P \< 0.05 Chi-square test.

Changes in eGFR are shown in [Figure 2](#F2){ref-type="fig"}. In the age group \< 65, eGFR decreased significantly from the baseline value of 89.0 ± 20.8 at all time points. At and after month 3, there was no significant change from month 3 value (3 - 6 months change -0.8 ± 9.5, P = 0.536; 3 - 9 months change -0.3 ± 10.6, P = 0.817; and 3 - 12 months change -1.7 ± 11.4, P = 0.232). In the age group 65 - 74, eGFR tended to decrease without significant change. In the age group ≥ 75, a significant decrease (-2.9 ± 9.4) was noted only at month 3; however, no significant change was noted after that time. The analysis results from the patients newly receiving alogliptin were similar to those from all patients; however, there was no significant intragroup difference in change from baseline in the age group \< 65 at month 3, with intergroup differences in change noted only at month 9 and month 12 ([Fig. 3](#F3){ref-type="fig"}).

![Changes in eGFR (all patients). \*P \< 0.05 versus 0 month, paired *t*-test; \*\*P \< 0.05, ANOVA. eGFR: estimated glomerular filtration rate; ANOVA: analysis of variance.](jocmr-11-651-g002){#F2}

![Changes in eGFR (patients newly receiving alogliptin). \*P \< 0.05 versus 0 month, paired *t*-test; \*\*P \< 0.05, ANOVA. eGFR: estimated glomerular filtration rate; ANOVA: analysis of variance.](jocmr-11-651-g003){#F3}

Changes in other parameters are shown in [Table 3](#T3){ref-type="table"}. HbA1c levels decreased significantly in all age groups at all measuring time points: the change at month 12 was -0.74±1.45% for the age group \< 65, -0.47±1.02% for the age group 65 - 74, and -0.42±1.11% for the age group ≥ 75. Significant differences in change were noted among the age groups only at month 3; however, after that time and until month 12, no difference was noted among the age groups. In the age group \< 65, the percentage of BG users significantly increased at month 12 compared to the baseline (P = 0.033, Chi-square test). However, in the patients who belong to the age group \< 65 and who did not newly begin using BG, HbA1c decreased significantly from the baseline value of 7.46 ± 1.41 to month 12 value of 6.78 ± 1.17 (P \< 0.001 paired *t*-test). Analysis of the patients newly receiving alogliptin also revealed change differences among the age groups at month 6; however, there were similar changes at other time points (Supplementary [Table 3](#T3){ref-type="table"}, [www.jocmr.org](http://www.jocmr.org)). With regard to changes in blood pressure, body weight, and BMI, there was no significant difference among the various age groups. Although some other parameters showed intergroup differences in change, none of them prevailed throughout the entire study period.

###### Efficacy Endpoints in the Full Analysis Set

                                         Age \< 65   Age 65 - 74   Age ≥ 75   P (ANOVA)                                                                                       
  -------------------------------------- ----------- ------------- ---------- ------------ ---- ------- ------- ------------ ---- ------- ------- ------------ -------------- --------------
  HbA1c (%)                              0 M         110           7.65       1.32              87      7.39    1.15              93      7.06    1.02                        0.002\*\*
  3 M                                    105         6.94          0.86                    84   6.90    0.71                 82   6.84    0.86                 0.722          
  6 M                                    93          6.84          0.81                    81   6.82    0.61                 82   6.64    0.71                 0.132          
  9 M                                    92          6.92          0.98                    71   6.80    0.67                 79   6.68    0.77                 0.186          
  12 M                                   96          6.90          1.07                    76   6.82    0.68                 76   6.74    0.81                 0.513          
  Δ3 M                                   105         -0.73         1.02       \< 0.001\*   84   -0.50   0.95    \< 0.001\*   82   -0.30   0.90    0.004\*      0.010\*\*      
  Δ6 M                                   93          -0.82         1.18       \< 0.001\*   81   -0.50   0.97    \< 0.001\*   82   -0.49   1.05    \< 0.001\*   0.066          
  Δ9 M                                   92          -0.73         1.28       \< 0.001\*   71   -0.49   0.86    \< 0.001\*   79   -0.41   1.10    0.001\*      0.155          
  Δ12 M                                  96          -0.74         1.45       \< 0.001\*   76   -0.47   1.02    \< 0.001\*   76   -0.42   1.11    0.002\*      0.180          
  Blood glucose (fasting) (mg/dL)        0 M         37            162.0      57.7              27      140.1   35.9              29      142.7   35.8                        0.111
  3 M                                    32          134.7         30.8                    23   151.0   48.9                 20   125.6   27.3                 0.073          
  6 M                                    26          126.8         30.3                    23   130.1   26.8                 21   132.7   22.7                 0.756          
  9 M                                    29          139.3         39.7                    21   138.1   39.7                 21   124.1   23.0                 0.287          
  12 M                                   30          132.1         48.4                    19   129.8   34.0                 17   134.1   35.5                 0.955          
  Δ3 M                                   27          -32.9         46.6       0.001\*      18   9.4     40.9    0.341        18   -15.9   30.1    0.039\*      0.005\*\*      
  Δ6 M                                   22          -23.4         37.4       0.008\*      19   -16.4   30.2    0.029\*      20   -18.1   22.6    0.002\*      0.749          
  Δ9 M                                   24          -25.3         56.3       0.038\*      18   -10.0   29.3    0.166        18   -26.9   36.8    0.006\*      0.437          
  Δ12 M                                  25          -39.6         66.8       0.007\*      17   -17.7   23.9    0.008\*      17   -13.7   38.0    0.157        0.197          
  Blood glucose (postprandial) (mg/dL)   0 M         42            189.4      63.8              38      180.3   63.6              37      188.9   78.2                        0.810
  3 M                                    39          162.3         55.0                    33   147.4   31.9                 34   165.2   45.2                 0.233          
  6 M                                    42          162.5         71.3                    32   161.2   47.6                 33   162.0   55.9                 0.996          
  9 M                                    36          161.9         58.7                    29   154\.   38.5                 28   176.7   61.9                 0.282          
  12 M                                   40          182.8         75.5                    37   160.9   44.4                 36   168.9   56.5                 0.278          
  Δ3 M                                   35          -20.7         50.4       0.021\*      30   -29.2   63.2    0.017\*      33   -7.5    51.9    0.415        0.291          
  Δ6 M                                   33          -24.4         44.0       0.003\*      30   -1.7    58.6    0.872        31   -15.6   61.2    0.165        0.264          
  Δ9 M                                   31          -23.3         58.6       0.035\*      26   -5.9    46.9    0.525        25   9.6     74.7    0.525        0.136          
  Δ12 M                                  36          -6.6          66.3       0.552        33   -18.1   69.6    0.145        33   -2.2    66.7    0.852        0.614          
  TC (mg/dL)                             0 M         74            197.3      35.8              48      193.6   34.2              41      185.1   27.4                        0.178
  3 M                                    64          192.5         35.5                    44   187.7   25.0                 35   182.5   31.7                 0.314          
  6 M                                    54          187.0         31.1                    40   185.8   30.5                 33   187.8   33.0                 0.959          
  9 M                                    50          186.1         29.9                    31   182.8   31.6                 27   176.8   30.7                 0.449          
  12 M                                   57          188.5         32.6                    34   189.3   32.6                 28   181.4   30.1                 0.560          
  Δ3 M                                   63          -3.0          30.4       0.432        43   -5.8    23.2    0.111        32   0.3     28.7    0.961        0.654          
  Δ6 M                                   54          -11.4         38.4       0.033\*      39   -9.4    26.1    0.031\*      32   1.7     31.2    0.766        0.194          
  Δ9 M                                   49          -15.3         33.3       0.002\*      31   -12.1   25.5    0.013\*      26   -3.7    23.5    0.426        0.258          
  Δ12 M                                  55          -12.7         32.2       0.005\*      34   -8.2    21.5    0.032\*      27   -1.0    24.7    0.841        0.199          
  LDL-C (mg/dL)                          0 M         76            119.1      30.3              68      109.9   30.5              66      108.5   24.2                        0.055
  3 M                                    65          113.8         27.0                    63   107.2   28.2                 46   105.1   24.3                 0.187          
  6 M                                    60          109.3         28.9                    54   108.1   29.3                 50   104.8   25.7                 0.697          
  9 M                                    50          106.3         22.8                    44   103.6   24.7                 41   104.3   28.1                 0.865          
  12 M                                   59          110.2         26.8                    52   106.4   24.3                 47   103.3   23.3                 0.361          
  Δ3 M                                   62          -6.5          31.5       0.109        62   -3.2    21.6    0.251        44   1.4     15.8    0.570        0.270          
  Δ6 M                                   57          -11.6         33.4       0.012\*      53   -3.1    20.3    0.269        49   -3.7    20.8    0.222        0.164          
  Δ9 M                                   47          -15.9         31.4       0.001\*      42   -7.9    27.0    0.064        40   -3.3    21.9    0.343        0.097          
  Δ12 M                                  56          -12.7         27.3       \< 0.001\*   52   -6.8    29.5    0.105        44   -4.1    21.5    0.208        0.252          
  HDL-C (mg/dL)                          0 M         90            52.0       12.4              69      56.7    13.3              74      56.0    13.6                        0.046\*\*
  3 M                                    80          52.4          12.2                    66   56.2    14.4                 53   55.0    14.2                 0.207          
  6 M                                    73          51.7          11.8                    54   56.0    12.6                 55   57.8    15.0                 0.025\*\*      
  9 M                                    67          52.0          13.4                    46   55.9    15.7                 46   56.2    13.8                 0.209          
  12 M                                   75          53.0          12.1                    51   55.0    11.9                 55   57.5    15.4                 0.167          
  Δ3 M                                   78          0.9           7.3        0.278        64   -0.4    5.7     0.615        51   0.2     7.9     0.860        0.561          
  Δ6 M                                   70          1.8           7.6        0.057        54   -2.1    7.4     0.043\*      55   1.7     8.0     0.127        0.011\*\*      
  Δ9 M                                   63          0.3           7.8        0.772        45   -1.6    8.6     0.208        46   0.8     7.3     0.472        0.298          
  Δ12 M                                  71          1.6           8.3        0.110        51   -2.4    6.7     0.015\*      53   0.9     7.9     0.427        0.017\*\*      
  TG (mg/dL)                             0 M         92            195.2      193.5             77      165.5   119.8             74      128.2   70.2                        0.012\*\*
  3 M                                    82          177.4         247.6                   74   153.1   101.4                55   133.3   89.8                 0.328          
  6 M                                    74          177.9         136.1                   63   148.0   93.1                 57   123.3   77.4                 0.017\*\*      
  9 M                                    68          164.4         100.2                   55   147.2   85.4                 48   122.1   64.9                 0.038\*\*      
  12 M                                   76          154.2         78.3                    61   149.5   91.5                 56   123.7   62.5                 0.073          
  Δ3 M                                   80          -4.4          209.1      0.850        73   -11.7   95.9    0.300        53   0.7     79.2    0.948        0.893          
  Δ6 M                                   73          -37.3         144.0      0.030\*      63   -10.9   104.1   0.409        57   -1.4    74.5    0.885        0.175          
  Δ9 M                                   66          -49.1         152.1      0.011\*      54   -14.3   85.8    0.227        48   1.2     52.6    0.874        0.046\*\*      
  Δ12 M                                  72          -24.0         117.8      0.089        61   -7.5    82.3    0.470        54   2.7     61.9    0.748        0.268          
  GOT (IU/L)                             0 M         78            31.6       21.3              69      26.2    12.9              69      24.8    11.7                        0.028\*\*
  3 M                                    67          29.2          18.0                    61   26.3    13.2                 48   25.7    11.0                 0.377          
  6 M                                    62          28.0          16.3                    56   26.1    12.4                 52   23.7    8.5                  0.221          
  9 M                                    53          28.9          17.6                    41   26.4    11.4                 38   25.6    20.7                 0.623          
  12 M                                   64          28.9          18.0                    50   28.5    18.0                 48   24.6    11.6                 0.335          
  Δ3 M                                   65          -3.1          18.0       0.164        58   -0.4    9.7     0.766        46   -0.2    5.5     0.852        0.371          
  Δ6 M                                   57          -2.3          17.2       0.324        55   0.4     11.4    0.804        51   -1.9    8.2     0.097        0.507          
  Δ9 M                                   51          -3.0          15.2       0.159        40   0.3     12.4    0.889        38   1.5     9.4     0.321        0.219          
  Δ12 M                                  58          -3.8          19.4       0.145        50   2.5     15.6    0.258        47   -1.0    11.9    0.583        0.135          
  GPT (IU/L)                             0 M         90            38.9       31.6              76      27.3    17.9              72      21.1    15.2                        \< 0.001\*\*
  3 M                                    81          34.5          24.0                    70   25.5    18.2                 54   20.8    14.6                 \< 0.001\*\*   
  6 M                                    72          35.9          33.5                    61   26.0    15.6                 56   18.3    11.1                 \< 0.001\*\*   
  9 M                                    65          32.4          20.6                    49   26.1    15.5                 43   21.2    14.0                 0.005\*\*      
  12 M                                   78          35.2          29.3                    55   28.3    20.9                 50   18.5    9.2                  \< 0.001\*\*   
  Δ3 M                                   78          -5.4          19.6       0.017\*      67   -1.2    12.7    0.438        51   -0.9    6.7     0.330        0.139          
  Δ6 M                                   68          -3.3          31.7       0.399        61   -0.1    11.2    0.964        53   -2.5    10.7    0.097        0.680          
  Δ9 M                                   62          -6.7          23.2       0.027\*      47   0.0     10.5    0.978        41   0.9     7.8     0.461        0.036\*\*      
  Δ12 M                                  72          -5.2          26.8       0.106        55   1.9     15.1    0.348        49   -2.5    12.3    0.166        0.148          
  γ-GTP (IU/L)                           0 M         81            56.7       51.9              65      45.0    57.2              71      40.6    69.3                        0.226
  3 M                                    69          53.5          59.9                    58   45.2    61.8                 50   44.3    69.2                 0.670          
  6 M                                    66          54.3          49.4                    49   52.4    66.1                 51   37.9    52.1                 0.248          
  9 M                                    57          54.3          49.6                    37   61.8    90.4                 42   55.0    123.5                0.915          
  12 M                                   68          49.0          42.9                    45   56.2    80.2                 50   36.6    61.8                 0.281          
  Δ3 M                                   66          -4.5          20.3       0.076        54   -0.1    19.5    0.972        49   -0.6    16.7    0.805        0.380          
  Δ6 M                                   61          -3.8          21.9       0.178        48   2.8     46.6    0.680        51   -5.7    35.6    0.256        0.451          
  Δ9 M                                   54          -3.4          23.9       0.302        34   6.4     70.9    0.602        42   10.3    49.9    0.188        0.363          
  Δ12 M                                  62          -5.1          27.7       0.151        44   4.0     65.0    0.682        50   0.7     67.8    0.945        0.680          
  Serum amylase (IU/L)                   0 M         30            59.9       25.3              17      67.0    19.3              11      83.6    24.7                        0.022\*\*
  3 M                                    21          64.9          23.0                    15   72.1    20.1                 11   88.6    23.5                 0.023\*\*      
  6 M                                    12          67.3          25.3                    13   71.4    20.3                 10   86.8    24.7                 0.144          
  9 M                                    5           63.6          14.9                    2    80.5    3.5                  4    80.0    17.4                 0.250          
  12 M                                   10          55.9          16.5                    9    76.0    21.2                 3    113.0   29.5                 0.001\*\*      
  Δ3 M                                   19          4.5           12.1       0.121        14   6.8     20.6    0.241        9    1.6     14.7    0.759        0.746          
  Δ6 M                                   12          8.0           9.7        0.016\*      11   13.4    17.2    0.028\*      7    1.4     14.8    0.807        0.229          
  Δ9 M                                   4           2.3           8.3        0.624        2    1.0     4.2     0.795        4    -4.8    27.0    0.749        0.860          
  Δ12 M                                  9           1.1           11.4       0.777        8    9.9     21.7    0.238        2    -8.5    31.8    0.770        0.392          
  Serum creatinine (mg/dL)               0 M         89            0.70       0.16              65      0.73    0.27              72      0.73    0.20                        0.458
  3 M                                    77          0.72          0.17                    60   0.75    0.27                 56   0.80    0.40                 0.283          
  6 M                                    73          0.73          0.17                    52   0.75    0.27                 58   0.76    0.19                 0.556          
  9 M                                    66          0.74          0.16                    46   0.75    0.32                 49   0.73    0.20                 0.856          
  12 M                                   77          0.76          0.17                    51   0.76    0.28                 56   0.75    0.18                 0.961          
  Δ3 M                                   74          0.04          0.08       \< 0.001\*   57   0.00    0.08    0.692        54   0.03    0.13    0.093        0.160          
  Δ6 M                                   69          0.03          0.08       0.002\*      52   0.02    0.10    0.122        56   0.01    0.10    0.355        0.578          
  Δ9 M                                   62          0.04          0.07       \< 0.001\*   42   0.03    0.08    0.012\*      48   0.01    0.10    0.378        0.157          
  Δ12 M                                  70          0.06          0.08       \< 0.001\*   50   0.02    0.08    0.045\*      54   0.01    0.10    0.319        0.016\*\*      
  SBP (mm Hg)                            0 M         108           133.0      17.2              86      132.3   13.3              91      137.5   21.5                        0.097
  3 M                                    103         130.1         13.7                    84   131.1   14.7                 87   135.2   16.4                 0.050          
  6 M                                    91          131.4         13.8                    81   130.8   14.1                 83   136.4   17.3                 0.035\*\*      
  9 M                                    85          131.3         13.4                    73   131.2   12.8                 80   134.0   15.4                 0.359          
  12 M                                   94          132.0         17.0                    75   130.6   11.3                 81   134.8   17.9                 0.244          
  Δ3 M                                   101         -2.6          15.2       0.094        83   -1.0    14.5    0.551        87   -2.7    18.1    0.171        0.731          
  Δ6 M                                   91          -1.4          14.7       0.352        80   -1.4    13.7    0.359        81   -1.4    18.6    0.498        1.000          
  Δ9 M                                   85          -2.0          15.6       0.244        72   -1.1    14.3    0.501        79   -3.8    21.1    0.117        0.634          
  Δ12 M                                  94          -1.0          16.5       0.567        74   -1.7    15.2    0.331        80   -4.2    20.8    0.074        0.465          
  DBP (mm Hg)                            0 M         108           80.0       11.4              86      73.2    10.0              91      74.0    10.4                        \< 0.001\*\*
  3 M                                    103         78.4          11.7                    84   74.3    9.6                  87   72.6    9.6                  \< 0.001\*\*   
  6 M                                    91          78.5          11.1                    81   73.4    9.8                  82   72.4    8.7                  \< 0.001\*\*   
  9 M                                    84          79.5          11.3                    73   72.4    9.0                  80   71.9    9.6                  \< 0.001\*\*   
  12 M                                   94          79.6          10.8                    75   73.6    8.4                  81   72.6    9.8                  \< 0.001\*\*   
  Δ3 M                                   101         -1.4          9.4        0.132        83   1.4     9.3     0.164        87   -1.7    12.4    0.196        0.093          
  Δ6 M                                   91          -1.5          8.0        0.075        80   0.3     8.3     0.717        80   -1.6    11.3    0.211        0.325          
  Δ9 M                                   84          -0.7          10.8       0.558        72   -0.3    9.8     0.829        79   -1.9    11.4    0.132        0.594          
  Δ12 M                                  94          -0.4          9.2        0.688        74   0.2     9.9     0.861        80   -1.5    9.1     0.148        0.524          
  Body weight (kg)                       0 M         104           73.05      14.71             77      62.58   10.49             85      57.56   10.47                       \< 0.001\*\*
  3 M                                    87          71.73         13.60                   69   61.64   10.28                65   57.11   11.50                \< 0.001\*\*   
  6 M                                    79          72.59         13.93                   65   61.26   10.18                66   56.50   11.29                \< 0.001\*\*   
  9 M                                    71          73.11         13.75                   55   60.90   10.54                61   57.51   11.04                \< 0.001\*\*   
  12 M                                   80          74.61         15.12                   62   61.63   10.50                64   57.47   10.69                \< 0.001\*\*   
  Δ3 M                                   86          -0.05         2.02       0.822        68   0.00    2.12    1.000        64   -0.39   1.50    0.042\*      0.442          
  Δ6 M                                   79          0.05          2.59       0.864        64   0.25    4.19    0.638        64   -0.33   1.62    0.112        0.538          
  Δ9 M                                   71          0.01          2.40       0.985        54   -0.29   1.90    0.274        60   0.07    2.47    0.819        0.676          
  Δ12 M                                  80          0.59          3.15       0.101        61   -0.25   2.07    0.347        63   -0.36   2.63    0.284        0.072          
  BMI (kg/m^2^)                          0 M         85            26.61      4.63              68      24.58   3.18              73      23.55   3.23                        \< 0.001\*\*
  3 M                                    69          26.38         4.21                    60   24.26   3.17                 54   23.14   3.43                 \< 0.001\*\*   
  6 M                                    62          26.72         4.14                    57   24.21   3.28                 54   23.16   3.30                 \< 0.001\*\*   
  9 M                                    53          26.68         3.87                    49   23.79   3.21                 50   23.58   3.15                 \< 0.001\*\*   
  12 M                                   62          27.21         4.75                    55   24.07   3.27                 54   23.45   3.03                 \< 0.001\*\*   
  Δ3 M                                   68          0.05          0.61       0.482        60   0.00    0.89    0.981        54   -0.19   0.65    0.037\*      0.166          
  Δ6 M                                   62          0.07          0.96       0.588        57   0.16    1.80    0.511        53   -0.18   0.71    0.066        0.337          
  Δ9 M                                   53          0.05          0.90       0.669        49   -0.07   0.74    0.521        50   0.07    1.05    0.648        0.713          
  Δ12 M                                  62          0.23          1.16       0.115        55   -0.09   0.80    0.402        54   -0.15   1.15    0.329        0.101          

SD: standard deviation; ANOVA: analysis of variance; HbA1c: hemoglobin A1c; M: month; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; GOT: glutamate oxaloacetate transaminase; GPT: glutamate pyruvate transaminase; γ-GTP: γ-glutamyl transpeptidase; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index. \*P \< 0.05 versus 0 month, paired *t*-test; \*\*P \< 0.05, ANOVA.

Hypoglycemia occurred in one patient in the age group \< 65 and one patient in the age group 65 - 74; constipation in three patients in the age group ≥ 75; neurological disease, hypertension, and dyslipidemia each in one patient in the age group \< 65; and bone fracture in one patient in the age group ≥ 75.

Discussion {#s4}
==========

The present study demonstrated that alogliptin was safe and effective in elderly Japanese patients. Even though serum amylase and creatinine were elevated for month 3 and month 6 after the administration, there were no cases that reported an adverse event.

eGFR decreased significantly in the age group \< 65 at month 3, after which time, however, the level remained constant, with no further reductions. The baseline eGFR for the age group \< 65 was somewhat high, at 89.0 ± 20.8. Increased eGFR also represents an unwanted condition, with excessive filtration due to hyperglycemia, suggesting a reduction in eGFR and a restoration of normal state. In the age group ≥ 75, eGFR decreased significantly by -2.9 ± 9.4 at month 3. However, at and after month 6, there was no significant difference, and the 12-month change was -1.5 ± 10.0; the significant difference is considered to have been a transient change. Our previous study of sitagliptin showed that eGFR decreased significantly in elderly subjects aged over 65; however, this parameter did not decrease in the patients with low baseline eGFR, although it decreased in the patients with high baseline eGFR \[[@R15]\]. Ujihara et al reported similar results \[[@R16]\]. Their study showed the eGFR change to be -2.7 ± 8.1 in elderly patients receiving sitagliptin for 3 months, a level similar to ours in the present study; it can be conjectured that there is no major difference in renal effects in the elderly between sitagliptin and alogliptin. This can be supported by the fact that the renal excretion rate in healthy adults does not differ widely between sitagliptin (87%) \[[@R17]\] and alogliptin (76%) \[[@R18]\].

HbA1c decreased significantly in all age groups. Our previous study of sitagliptin showed significant reductions in HbA1c irrespective of age group \[[@R15]\]; similar results were obtained with alogliptin in the present study. In terms of changes at month 3, on the other hand, age-related differences were noted. We previously reported that the full-set analysis in the ATTAK-J study showed HbA1c to decrease with increasing initial HbA1c level and with decreasing duration of disease \[[@R05]\], and this may have influenced the results of the stratified analysis in the present study, in which the young subjects had higher HbA1c levels and shorter duration of disease. The age-stratified analysis in the present study showed satisfactory control of HbA1c to be 6.84 ± 0.86 at month 3 in the age group ≥ 75; the study drug was not weakly effective in blood glucose reductions. DPP-4 inhibitors improve blood glucose control by increasing insulin secretion with a dependence on blood glucose level via inhibition of glucagon-like peptide-1 (GLP-1) inactivation and DPP-4-mediated action, thus inhibiting glucagon secretion \[[@R19], [@R20]\]. This finding of HbA1c represents the characteristic dependence of the effects of the study drug on blood glucose. A meta-analysis of non-Japanese data by Pratley et al found a change in HbA1c of -0.8% in the ≥ 65 age group at month 26 of alogliptin treatment \[[@R13]\], which was greater than the -0.5% change in the present study. This difference is attributable to the fact that the 8.0% initial HbA1c level reported by Pratley et al \[[@R13]\] was higher than the baseline HbA1c levels of 7.06% to 7.39% in the elderly subjects in the present study.

In the elderly, kidney dysfunction can delay drug excretion and pose a hypoglycemia issue due to blood-glucose-lowering drugs. In the present study, hypoglycemia occurred at low incidences (i.e. in one patient in the age group \< 65 and one patient in the age group 65 - 74). This result demonstrates safety of alogliptin treatment in the elderly. One study reported, however, that severe hypoglycemia due to the use of a blood-glucose-lowering agent was likely to occur in the elderly \[[@R21]\]. Patients at ≥ 75 years of age often have disorders in cognitive and/or physical function \[[@R22]-[@R26]\], and their hypoglycemic symptoms are likely to be overlooked, which in turn can lead to symptom exacerbations \[[@R27]\]. Even with the use of DPP-4 inhibitors, which exhibit their effects with blood glucose dependence, it will continue to be necessary to encourage patients to be aware of their subjective symptoms of hypoglycemia to ensure that signs will not be overlooked.

No significant changes in BP were observed in any group, nor was there any intergroup difference. Although BW decreased significantly by -0.3 ± 1.5 kg at month 3 in the age group ≥ 75, this decrease is considered to have no influence on the safety, since there was no significant difference at or after month 6, and the changes were small and transient. The results for effects on lipid and liver function markers were similar to the previously reported full analysis results. Although subanalysis results revealed some tendencies not found in the full-set analysis results, the HDL-C reductions in the age group 65 - 74 and GPT reductions in the age group \< 65 are attributable to higher baseline values of the respective parameters.

The results for the effects of alogliptin in elderly subjects in the present study showed tendencies similar to those for the effects of sitagliptin in elderly subjects in our previous study. Which of the two drugs is superior remains unknown, because of the absence of direct comparisons with a study population of elderly subjects only; however, it seems that there is no major difference in the efficacy or safety up to 1 year of treatment. Although many studies have compared the effects of different DPP-4 inhibitors in an analysis including young subjects, they reported variable results for blood glucose control effects and inconsistent judgments concerning the superiority of the drugs \[[@R28]-[@R35]\]. Meta-analyses have not found any significant difference in hypoglycemic action among different DPP-4 inhibitors \[[@R36], [@R37]\]. In a meta-analysis focusing on alogliptin, Kay et al compared the effects of alogliptin with those of four other DPP-4 inhibitors (linagliptin, saxagliptin, sitagliptin, and vildagliptin) in patients with insufficient blood glucose control by treatment with metformin and sulfonylurea (SU), reporting that alogliptin did not differ from the other DPP-4 inhibitors in terms of efficacy and safety \[[@R38]\]. The excretory pathway differs among DPP-4 inhibitors. Alogliptin, sitagliptin, anagliptin, omarigliptin, and trelagliptin are excreted as unmetabolized drugs mainly from the kidney into the urine. Vildagliptin and saxagliptin are metabolized mainly in the liver. Linagliptin is excreted from the biliary system, and teneligliptin is metabolized in the liver and excreted from the renal system. In the elderly, in particular, the excretory pathways for these drugs can influence their safety; therefore, further evidence must be compiled.

As stated in the Introduction, Japan is facing an issue of preventing initiation of hemodialysis due to exacerbation of diabetic nephropathy. In October 2017, the Japanese Society of Nephrology and Japan Diabetes Society jointly adopted the Strategic Action Plan for Diabetic Kidney Disease (DKD) \[[@R39]\]. Since that time, these groups have been collaborating on implementation of DKD status surveys, elucidating its pathology, and developing new treatments. The present study showed alogliptin to be effective and safe in the treatment of elderly patients, providing valuable therapeutic evidence for elderly people as incipient diabetics. Generally, clinical trials include relatively small proportions of elderly subjects both in and outside Japan; data obtained for elderly subjects prior to the approval of the study drug can be insufficient. Conducted as a survey in actual clinical settings, unlike clinical trials, the present study is of great clinical implication by providing such data as valuable evidence for diabetic treatment.

Limitations {#s4a}
-----------

The present study lacked a control group, because it was conducted in an open-label retrospective fashion. In addition, no data on concomitant use with sodium-glucose transport protein 2 (SGLT2) inhibitors were available, because they were not approved at the time the data were obtained. Patients with GLP-1 receptor agonists were not included in this study. There are two backgrounds. One is that we acquired retrospective data at that time when DPP-4 inhibitors were approved. Another is that in our study subject, DPP-4 inhibitors were better suited for patients than GLP-1 analogues. The study was not based on accurate power calculations, because of its nature as an exploratory analysis.

Conclusions {#s4b}
-----------

Alogliptin significantly lowers HbA1c levels in the elderly and can be used without posing any safety issues, including renal effects, thus contributing to safe blood glucose control in clinical practice.
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